Cancer, Bartonella, Breast Cancer discussed on Lyme Ninja Radio - Lyme Disease
Patient so Anyway only as a physician I feel like I said so. So this is how this is how we treat cancer. We don't do this blindly anymore We really try to tailor the therapy personalized therapy for the individual. So this was. This was a drug that I spent Doing a lot of the science behind we developed an oral therapy for women with what's called hurts hurts to breast cancer. It's about fifteen to twenty percent of breast cancer when I was training Years ago at the Dana Farber. This was a death sentence of women who had her breast cancer announced. There had about six to nine months with metastatic disease and even with early stage. The risk of recurrence was extraordinarily high. This is an oral therapy. This woman has what's called inflammatory breast cancer. You can see that. She's had a mastectomy. It's come back that's like having a third degree. Burn that that went all the way down her back eroding into her lung cavity and into her lungs she was on a morphine drip not only a short quality of life for inflammatory breast cancer sir. But it's a lousy quality of life. We put her on this pill once a day pill and literally within three weeks. She was out playing Golf I. I didn't actually believe the physician when he told me. This is a miracle therapy but it's a miracle because we figured out how to shut the lights out on the tumor Sela aw again. This happened by understanding the biology and taking advantage of the Achilles heel of these particular cancers and so the question is why. Can't we do this for beryllium for Bartonella for BBC. The answer is we can. And here's a potential roadmaps it. Here's a paper that was published in Nineteen Ninety seven so twenty two years ago. I haven't been to too many conferences in the lime disease. World where people I actually talked about the genomic roadmap for developing therapies so this was the genome that was published in this is essentially the pathways. He's in Berea where one can look and try to figure out. How can we kill these bugs without taking an atomic bomb and blowing up the body audie and do this in a smart way just as I showed you without rather than giving her chemotherapy giving her a pill that reveal the old the Achilles heel of that cancer and destroyed it? So this is what we've done so we've taken slightly different approach. We're not screening the FDA approved Library Library. We're developing new therapies based on scientific information. Now we've done this in a way and brought in collaborators. It turns out that there's a group at Argonne national lab outside Chicago who have the largest genomic database of Pro Kerry outs bacteria in the world and then their top ten list. This is Barack Obama and Bartonella which I thought was rather interesting because this lab is a department of Energy Lab and I thought it was interesting that the government has beryllium Bartonella Ella as part of their top ten in trying to collect information so for a disease that a lot of the government doesn't want to recognize as being important. It's important Gordon enough. That it's on their top ten list of getting all genomic information of the world to accumulate so we worked with this group and what we do. We have the technology and collaboration with a very good friend and colleague who I've worked with for thirteen years since I've been in two on the cancer side Tim. Hey Stud and I'll show you the picture of our eighteen later we have a way of capturing a part of the genome a part of the what we call the purdy on the proteins that are made in Borelli and Bartonella that happened to utilize ATP and other appearance And it turns out if we use this technology. That's about eighty to ninety percent of the drug targets and again this is an approach that has been successfully used in other diseases and cancer in metabolic disease so so we're not reinventing the wheel retaking successful lessons that have been learned elsewhere and now just simply sang. Can we do the smarter by treating folks with tick borne illnesses and so essentially we do. Is We take the bacteria And again when we identify target. We've we've gone to this huge genomic database because we don't want to just be treating one particular species or strain of BEREA WE WANNA be treating reading across the species and strains that are pathogenic same with Bartonella. I'm but we don't want to also be wiping out the normal microbiome and we certainly certainly don't want to be affecting host cell so we don't want to be affecting your heart your kidney your normal tissues and so this is a Gel. This is taking taking all the proteins and beryllium running out And then essentially saying what are the targets that are amenable. What are the protein targets with this technology? -nology this pure and binding technology. We have this huge list of proteins. We painstakingly do mass SPEC on every one of these to identify them and then we look and we try to glean information from the literature and from experts and say what are the ones that if we can successfully target are likely to kill these bugs. I'm just going to skip through. This is some of the technical aspects. We take each one of these targets. This is sort of laborious research although we have a tremendous team and we've got it down pretty quickly now almost like a biotech company. Even though we're in an academic institution we make recombinant proteins. We put the color. GFD Green fluorescent thirteen and we have with high throughput outside. We've got five thousand novel compounds. That could be drugs and we screen them to see which those five thousand compounds can target the particular protein target that we're interested in by the way the five thousand doesn't sound like like a lot but we can expand that based on the structure of those chemicals into hundreds of thousands of compounds very quickly and and so this is what we have so far so we have targets on the left DNA K.. Beryllium Beryllium. We've had a lot more in beryllium important. We're now working with at British Werthmann if you know him from the NC State School of Veterinary Medicine. Probably the leading expert on Bartonella And now we've got several new BARTONELLA targets And as of of our last live meeting on to say I think we have an exciting Bartonella target that. We're going to be able to do what I'm going to show you in a minute. We're doing with beryllium. So this is work that we've done again With Tim set of colleague. That'll introduce what I want to show you which we hope will end up being a beryllium scan so that you could go to your doctor and rather than saying how many bands on a Western blot or do you have positively. You can actually visualize the bacteria in your body so if you went into your doctor imagine you said I got pain in my left shoulder. I got chest pain and I think I was bitten by a tick rather than having all these questions. You could actually visualize it just like we do with cancer and see the bugs. This is really based again on lessons. That have been successfully translated from the bench into the clinic. So this is work. We had a large Defense Department grand for breast cancer where we developed a probe using human Heat shock protein ninety. It's very abundant protein. There happens to be a beryllium equivalent called ht PG high temperature protein G. It's a very important protein. In mammalian cells age. Just be ninety because it prevents damage protein from accumulating which if allowed to accumulate would kill the cells. Also it's it's a highly conserved evolutionary family of proteins that protects against environmental stresses or internal stresses cell. The damage protein. That would otherwise. Kill the cell so what we did. In this case as we took H. S. P. Ninety an inhibitor. We labeled it with a probe that could be visualized and in a sense you unfortunately lighting. You can't really see it but we could visualize tumor in these. He's mice growing human breast cancers over normal tissue. And so the idea of this is if a woman has mammography has an abnormality and only ten percent one of those turn out to really be cancer that rather than doing unnecessary biopsies unnecessary angst. That you could do scan that would discriminate between malignant normal tissue issue and also ideally identify areas. What we call minimal disease states that are hiding in the body? This is actually in the clinic now and so what we did. Is We targeted the beryllium form of. HSBC ninety again is called H. G. and to make a longer story short we looked for compounds in the library and also compounds that we already developed against the human form of HSP Ninety for Breast Cancer Hanser project looking for compounds that would identify beryllium But not the human form because again. If we're GONNA make a scan and a therapeutic we don't don't want this targeting human tissue and also selecting for compounds that don't that can discriminate between Berea and and the normal microbiome Casey Choline and so we found this compound. It's called one ninety six and a few others this normally twirls around. But I don't think I have the controls for it so these are just spiral so in the left. I call it the Hawaiian Islands. The one nine thousand eight so the probe for the beryllium proteins and again this targets a protein in Borelli very abundant in beryllium. Bergdorf Roy Moore it is across the species and strains so we're not targeting just five percent of people with lung. Disease were selecting targets in this case for imaging. But I'll show you how we're using it for therapeutic that will affect fact all of the species and strains so we went from beryllium growing culture to working with Monica embers the two lane And doing a mouse study where we infected the mice with beryllium. We waited three weeks and then we injected the probe and we wanted wanted to see whether it would identify gorilla in tissues and again the bluish is the ninety eight so he could see. Infected Animals There's cartilage from the ear which is where beryllium loves to hang out. There's also the joint to joint. You could see that using the one nine eight probe the bluish probe We could identify really a- These are just obviously localized Images and then we counter stain when we take take the tissue out with a beryllium antibody to make sure that what that probe is identifying as beryllium and in fact it does and now. We're doing in Vivo. Animal Demel studies where we're going to visualize in Vivo. Knows are ongoing as we speak to see if we could actually scan now this. This fluorescent probe is is not prime time for for the clinic because it does not get good depth in the body so we could scan and probably visualize cartilage infected cartilage or the joint but to get the heart and brain. This is not gonna be sufficient so what we will do is to make pet league from this to take this and making pet scan. Most people heard of a pet scan. Not your dog or cat. But essentially a pet scan for the most part is a scam that f. d. g. pad it's taken up by hyper metabolic tissues and can identify in my case where my profession has cancer but also also infection. It doesn't tell you though if if it lights up and you think you have an infection. What the underlying infectious agent is? It just tells you that there's an infection action this on the other hand as a pet scan would tell you that's beryllium infection. So now so that's great right so we wanted to develop a beryllium Stan. We also have some targets that we want to look out for Bartonella because unfortunately this particular target for whatever reason is is not in the genome of Bartonella and so we have to look at other particularly pro teams so in the cancer world so now people may have screened one with these drugs these HSP ninety inhibitors through the FDA approved library because there are several that have gone into the clinic and cancer and maybe found that by themselves mm selves. They don't do much to really because they don't their stress proteins. You have to do something to the cell to make them relevant you. Don't just give them to happily. Holy growing beryllium doesn't kill them. That's not the way it works doesn't do that to human selves either. So what we did is and again. This is based on the lessons. Sounds from cancer where people have taken targeted therapies. Rather just relying on the targeted therapies have hooked up poison or a toxin. So this is kind The magic bullet where you drive the toxin directly to the cancer and avoid normal tissues. This happens to be a drug called. T. DM one which is an anti her two antibody but the drug called by chancing which is a my totic poison This is in the clinic. It's transformed the treatment. Seven of The Area I've been working on her to breast cancer. So what happens is the antibody recognizes the tumor cells because the her two is more prevalent Expressed on tumor cells. It has little stars on there which the Montana it gets internalized in the tumor. It releases the my Tam San and kills the tumor cells but really does oh spare the normal tissue so this is FDA approved and we said why can't we take the same compound that is directing that imaging agent that I just showed you and hook something onto it that'll bring it into guerrilla that'll kill Berea and spare normal tissue. So what does Borelli. Okay what are the things that really hates one of the things that most cells hate radical oxygen species. You know it's interesting. We've gotten very accustomed to growing beryllium now. Beryllium hates oxygen. Even though it's not a complete anaerobic but it likes living in low oxygen tension. So if you you stress these bacteria I don't care whether they're in a exponential speyrer Keitel studied around bodies state with lots of oxygen radicals. It's it's a death sentence is I'm going to show you. So what did we cook that compound so we actually have a drug.